First Manhattan’s Sana Biotechnology SANA Stock Holding History

First Manhattan’s Portfolio SANA Stock Details SANA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-200	Closed	-$1K	–	1772
2022 Q3	$1K	Hold	200	–	–	﹤0.01%	1478
2022 Q2	$1K	Hold	200	–	–	﹤0.01%	1505
2022 Q1	$1K	Hold	200	–	–	﹤0.01%	1550
2021 Q4	$3K	Buy	+200	New	+$3.86K	﹤0.01%	1455

Other funds holding SANA

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Public Sector Pension Investment Board (PSP Investments) Montreal, Quebec, Canada $38.7B AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

First Manhattan's SANA Position: Q4 2022 in Review

First Manhattan sold out of Sana Biotechnology (SANA) in Q4 2022, closing a stake of 200 shares — an estimated $1K sold.

First Manhattan first reported a position in SANA in Q4 2021 and held it in 4 quarters. The position peaked at $3K in Q4 2021. 119 funds tracked by Wall St. Rank hold SANA as of Q4 2022.

First Manhattan reported no remaining Sana Biotechnology position as of Q4 2022 after selling out during the quarter.
First Manhattan sold 200 Sana Biotechnology shares in Q4 2022, an estimated $1K.
First Manhattan first reported a position in Sana Biotechnology in Q4 2021 and held it in 4 quarters.
First Manhattan's Sana Biotechnology position peaked at $3K in Q4 2021.
119 funds tracked by Wall St. Rank held Sana Biotechnology as of Q4 2022.

Based on First Manhattan's 13F filing for Q4 2022, filed 14 Feb 2023.